Abbink, PeterPeterAbbinkLarocca, Rafael ARafael ALaroccaDejnirattisai, WanwisaWanwisaDejnirattisaiPeterson, RebeccaRebeccaPetersonNkolola, Joseph PJoseph PNkololaBorducchi, Erica NErica NBorducchiSupasa, PiyadaPiyadaSupasaMongkolsapaya, JJMongkolsapayaScreaton, Gavin RGavin RScreatonBarouch, Dan HDan HBarouch2018-04-252018-12-042018-06-04Nature Medicine, 2018, 24, pp.721-7231078-8956http://hdl.handle.net/10044/1/58680Strategies to treat Zika virus (ZIKV) infection in dengue virus (DENV) endemic areas are urgently needed. Here we show that a DENV-specific antibody against the E-dimer epitope (EDE) potent ly cross-neutralizes ZIKV and provides robust therapeutic efficacy as well as prophylactic efficacy against ZIKV in rhesus monkeys. Viral escape was not detected, suggesting a relatively high bar to escape. These data demonstrate the potential for antibody-based therapy and prevention of ZIKV.© 2018 Nature America Inc., part of Springer Nature. All rights reserved.Science & TechnologyLife Sciences & BiomedicineBiochemistry & Molecular BiologyCell BiologyMedicine, Research & ExperimentalResearch & Experimental MedicineVIRUS-INFECTIONCROSS-REACTIVITYVACCINEPOTENTENHANCEMENTCHALLENGE11 Medical And Health SciencesImmunologyJournal Articlehttps://www.dx.doi.org/10.1038/s41591-018-0056-0MR/N012658/1203224/Z/16/Z